|
Listen to article
|
For the first time in the history of malaria treatment, there is a medicine specifically designed for the youngest children who die from it. The World Health Organization announced Friday that it had granted prequalification approval to artemether-lumefantrine, an antimalarial formulation developed for newborns and infants — an age group that has until now been treated with drugs formulated for older children, creating persistent risks of dosage error, adverse side effects and toxicity in bodies too small and too vulnerable to absorb the imprecision.
The approval is not a minor procedural milestone. It closes a gap that has existed for as long as malaria treatment has existed — the gap between the patients dying in the greatest numbers and the medicines designed to save them. In 2024, malaria killed an estimated 610,000 people across 80 countries, from a total of 282 million cases. Africa accounted for 95 percent of both figures. Among the dead, three-quarters were children under five. Newborns and infants, the most fragile within that already devastating category, have been managed with whatever approximation of correct dosage caregivers and clinicians could calculate from medicines that were never built for them.
Read also: WHO Suspends Gaza Operations After Contract Worker Is Killed
“For centuries, malaria has stolen children from their parents, and health, wealth and hope from communities,” WHO Director-General Tedros Adhanom Ghebreyesus said. “But today, the story is changing. New vaccines, diagnostic tests, next-generation mosquito nets and effective medicines, including those adapted for the youngest, are helping to turn the tide. Ending malaria in our lifetime is no longer a dream — it is a real possibility, but only with sustained political and financial commitment. Now we can. Now we must.”
WHO prequalification means the medicine has been independently verified to meet international standards of quality, safety and efficacy — a designation that matters practically because 70 percent of countries globally lack regulatory systems robust enough to evaluate medicines independently. For those countries, WHO prequalification is the gateway through which a medicine becomes eligible for public sector procurement and international aid funding. Without it, a drug that works in a laboratory cannot reliably reach the clinics and community health posts where it is needed.
The approval is expected to enable procurement for the approximately 30 million babies born each year in malaria-endemic areas of Africa — children who enter the world in environments where the disease is not a distant risk but an immediate one, and who have been among the most underserved by a treatment landscape that developed around older patients.
Read also: Otti: Abia Healthcare Facilities Meet WHO Global Standards
Artemether-lumefantrine in its existing forms is already one of the most widely used antimalarial treatments globally, recommended by the WHO as a first-line therapy for uncomplicated malaria caused by Plasmodium falciparum. The new formulation adapts the same active compounds for the pharmacological realities of newborn and infant physiology — different absorption rates, different metabolic pathways, different tolerances for the concentrations that work safely in older children or adults.
The approval arrives at a moment when the WHO is explicitly warning that progress against malaria is under threat from multiple converging pressures. Drug resistance is developing in parts of sub-Saharan Africa and Southeast Asia, reducing the effectiveness of first-line treatments. Insecticide resistance is compromising the mosquito nets that remain one of the most cost-effective tools in malaria prevention. Diagnostic failures are allowing cases to go undetected and untreated. And sharp reductions in foreign aid spending — driven by fiscal pressures in donor countries and shifting political priorities — are cutting the funding streams that have supported malaria programmes across the continent for two decades.
Against that backdrop, Friday’s approval offers something the WHO has been careful to contextualise rather than overstate: a genuine advance in the toolkit, conditional on the political will and financial commitment to deploy it at the scale the problem requires. Tedros was direct about that conditionality. The possibility of ending malaria in this generation exists. It does not guarantee itself.
For the parents of the 30 million infants born annually in malaria-endemic Africa, the approval means something more immediate than a policy milestone. It means that when their child develops a fever, the medicine waiting at the health post was made for that child — not adapted, not approximated, not calculated from a dosing chart designed for someone older and larger. It was made for them. That has never been true before.
